Multisystem inflammatory syndrome after SARS-CoV-2 vaccination (MIS-V), to interpret with caution

The introduction of safe and effective vaccines to prevent SARS-CoV-2 infection has been one of the key strategies in the global control of COVID-19 pandemic as they help in preventing SARS-CoV-2 infections (both symptomatic or asymptomatic), severe illness, COVID-19–related hospitalisation and mortality.1 Side effects from COVID-19 vaccinations are usually minor and include local pain at injection site or general musculoskeletal features. There are multiple reports of adverse events following vaccination (AEFI), however, as causation is often not established, such AEFI must always be interpreted with caution.

Multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A) after COVID-19 infection has been described in the UK, Europe and the USA. This may lead to a poor prognosis if not diagnosed and treated early.2 3 A similar multisystem inflammatory syndrome has recently been reported following SARS-CoV-2 vaccination (MIS-V).4 5 Since MIS-V is a rare entity, the Centers for Disease Control and Prevention and US Food and Drug Administration comanaged the Vaccine Adverse Event Reporting System and are actively monitoring the same. The exact incidence, prevalence and pathophysiology of MIS-V are unclear till date. Theories of dysregulation of the immune system, cytokine storm and/or hyper-reactivity of the immune system due to a preceding asymptomatic or symptomatic COVID-19 infection have been suggested.4 However, subclinical SARS-CoV-2 infection around the time of vaccination leading on to MIS which is misattributed to vaccination is also a possible aetiology. Concurrently, the patients may have a positive test result for SARS-CoV-2 antigen or antibody assays, indicating recent COVID-19 infection, with a background of recent history of a COVID-19 vaccination.

The affected patients appear to present shortly after having received COVID-19 vaccination, with febrile illness and a constellation of symptoms affecting the gastrointestinal, cardiovascular, renal, vascular, dermatologic and neurologic systems, without features of severe primary respiratory illness. Definitive, probable and possible diagnostic Brighton Collaboration criteria are applied to formulate management plans.3 Patients with MIS-V have markedly elevated laboratory markers of inflammation and coagulopathy. However, in view of varied clinical and laboratory profile and a rare occurrence, it is imperative to rule out other aetiologies including a recent or active COVID-19 infection. Management and treatment strategies for MIS-V are predominantly centred around the doctrines of managing MIS-C and MIS-A with an early recognition of the condition, high index of suspicion and principles of supportive measures including immuno-modulatory therapy.6

The paediatric population is at a higher risk for MIS. Currently, trials are underway for the safety and efficacy of COVID-19 vaccination in children. Temporal association of MIS is not same as causation and MIS-V entity, which may soon be increasingly reported in children, must be interpreted with caution. A misattribution of MIS to vaccination can lead to increased vaccine hesitancy and blunt the global COVID-19 vaccination drive. Thus, strict surveillance, detailed evaluation and laboratory investigations to rule out active or recent COVID-19 infection and potential other causes must be carried out in all patients before attributing it to MIS-V after COVID-19 vaccination.

Karthikeyan P Iyengar, Arvind Nune, Pranav Ish, Madapura K Shashidhara, Vijay Kumar Jain

1Department of Trauma and Orthopaedics, Southport and Ormskirk Hospital NHS Trust, Southport, UK
2Department of Rheumatology, Southport and Ormskirk NHS Trust, Southport, UK
3Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, New Delhi, India
4Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, UK
5Department of Anaesthesiology, Stepping Hill Hospital, Stockport, UK
6Department of Orthopaedics, Atal Bihari Vajpayee Institute of Medical Sciences, Dr Ram Manohar Lohia Hospital, New Delhi, India

Correspondence to Karthikeyan P Iyengar, Southport and Ormskirk Hospital NHS Trust, Southport PR8 6PN, UK; kartikg31@hotmail.com

Contributors KPI was involved in conceptualisation, literature search, writing the original draft of manuscript, planning, conduct and editing. AN, PI, RB, MKS and VKJ were involved in review and editing. All authors have read and agreed with the submitted manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Accepted 22 August 2021
Postgrad Med J 2021:1. doi:10.1136/postgradmedj-2021-140869

ORCIDs
Karthikeyan P Iyengar http://orcid.org/0000-0002-4379-1266
Arvind Nune http://orcid.org/0000-0002-3849-614X
Pranav Ish http://orcid.org/0000-0003-1701-4970
Vijay Kumar Jain http://orcid.org/0000-0003-4164-7380

REFERENCES